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DEVELOPMENT OF A PNEUMOCOCCAL CONJUGATE VACCINE DRUG PRODUCT: ENSURING
STABILITY, A ROBUST MANUFACTURING PROCESS AND LONG-TERM COMMERCIAL
SUSTAINABILITY
William J. Smith, Merck and Co. Inc., USA
william_smith2@merck.com
Successful development, commercialization and life cycle management of a vaccine drug product represents a
significant challenge. For effective, broad-strain pathogen coverage, an antibacterial vaccine often contains
multiple antigens formulated at low concentration in the presence of an adjuvant. Due to the complex nature of
a vaccine drug product formulation, understanding how manufacturing, packaging, shipping, and storage
temperature impacts the underlying physicochemical properties of the drug product is critical. Due to the
complexity of the human immune system, if chemical or physical changes occur, comprehending how these
changes impact clinical efficacy can be daunting. Therefore, efforts should be directed toward ensuring
chemical, physical, and colloidal stability and design of a drug product formulation that has a scalable and
robust process early in the preclinical space that can be successful throughout clinical operations and eventually
in the commercial phase of the program. As one strives to supply vaccines to developing and emerging
markets, increasing focus should be directed to ensuring not only a robust manufacturing process but enhanced
thermal stability of a vaccine drug product.
As a case study, a vaccine comprising the Pneumococcal polysaccharide (PnPs) serotypes (1, 3, 4, 5, 6A, 6B,
7F, 9V, 14, 18C, 19A, 19F, 22F, 23F & 33F) covalently attached to the protein carrier, CRM197, was evaluated
(PCV15). Using a combination of in vivo and in vitro tools, Aluminum Phosphate Adjuvant (APA) was selected
to ensure chemical stability and target potency in the drug product formulation. To ensure line of sight to a
robust manufacturing process, experiments were completed to create a scale-down model to better predict the
impact of expected manufacturing and shipping stresses on the vaccine drug product. Using this scale-down
model, the drug product formulation for PCV-15 was optimized to provide significant protection from aggregation
induced by manufacture and shipping and handling.
These collective efforts have allowed for design of a scalable and stable drug product formulation process early
in the preclinical space that was found to be successful throughout clinical development and now as positioned
in the commercial phase of the program.

Thursday, June 16, 2022

Session 9: Formulation and delivery

